Design, synthesis and anticolorectal cancer activity of 2- bromoalkoxyanthraquinones

The impact of alkoxy chain length and the presence of a 1-hydroxy group in synthesised 2-bromoalkoxyanthraquinones was evaluated against HCT116, HT29, and CCD841 CoN cell lines. Molecular docking was employed to elucidate the interactions between these compounds and potential p53 and KRAS targets...

Full description

Saved in:
Bibliographic Details
Main Authors: Lee, Yean Kee, Nurhaliza, Wati Mekzali, Cheok, Wui Chee, Iskandar, Abdullah, Nurshamimi, Nor Rashid, Vannajan, Sanghiran Lee, Rozana, Othman, Najihah, Mohd Hashim, Chin, Fei Chee
Format: Conference or Workshop Item
Language:English
English
Published: 2024
Subjects:
Online Access:http://eprints.um.edu.my/45060/1/Lee%20Yean%20Kee-ACP2023-Abstract.pdf
http://eprints.um.edu.my/45060/2/Lee%20Yean%20Kee-ACP2023-Poster.pdf
http://eprints.um.edu.my/45060/
https://icceoca16.sg/
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaya
Language: English
English
Description
Summary:The impact of alkoxy chain length and the presence of a 1-hydroxy group in synthesised 2-bromoalkoxyanthraquinones was evaluated against HCT116, HT29, and CCD841 CoN cell lines. Molecular docking was employed to elucidate the interactions between these compounds and potential p53 and KRAS targets. Results indicated that 2-bromoalkoxyanthraquinones with the 1-hydroxy group exhibited greater anticancer activity compared to their counterparts. Specifically, compound 6b bearing C3 alkoxy chain displayed the most promising antiproliferation activity against HCT116 cells (IC50 = 3.83 ± 0.05 μM) and demonstrated high selectivity for HCT116 over CCD841 CoN cells (SI = 45.47). Molecular docking analysis revealed additional hydrogen bonds between the 1-hydroxy group of 6b and the proteins. Compound 6b also exhibited adequate lipophilicity (cLogP = 3.27) and ligand efficiency metrics (LE = 0.34; LLE = 2.15) within the acceptable range for an initial hit. This study underscores the potential of the 1-hydroxy group and a short alkoxy chain in enhancing the anti-colorectal cancer activity of 2-bromoalkoxyanthraquinones. Further optimisation should be possible for compound 6b as a potential therapeutic agent against colorectal cancer.